In situ protein detection for companion diagnostics

Frontiers in Oncology

Volumn 3 OCT, Issue , 2013, Pages

  Gremel, Gabriela ^a   Grannas, Karin ^a   Sutton, Lesley Ann ^a   Pontén, Fredrik ^a   Zieba, Agata ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alternative binders; Companion diagnostics; Her2; Immunohistochemistry; Proximity ligation assays

Indexed keywords

AMYLOID BETA PROTEIN; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; CRIZOTINIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; IMATINIB; INTERLEUKIN 2; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN; VEMURAFENIB; VON WILLEBRAND FACTOR;

BREAST CANCER; CANCER DIAGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMPANION DIAGNOSTICS; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84891084710     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00271     Document Type: Review

References (134)

1. Jorgensen JT. Companion diagnostics in oncology-current status and future aspects. Oncology (2013) 85:59-68. doi: 10.1159/000353454
2. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med (1981) 305:1-6. doi:10.1056/NEJM198107023050101
3. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol (1983) 1:227-41.
4. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11:155-68.
5. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer (1996) 74:1445-51. doi:10.1038/bjc.1996.563
6. Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer (2006) 13:232-5. doi:10.2325/jbcs.13.232
7. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res (1989) 49:1052-6.
8. Rhodes A, Jasani B, Barnes DM, Bobrow LG, Miller KD. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 53:125-30. doi:10.1136/jcp.53.2.125
9. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol (2000) 53:688-96. doi:10.1136/jcp.53.9.688
10. Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol (2007) 60:1277-83. doi:10.1136/jcp.2006.044701
11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 134:e48-72. doi:10.1043/1543-2165-134.7.e48
12. Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (1975) 189:726-7. doi:10.1126/science.168640
13. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med (1983) 309:1343-7. doi:10.1056/NEJM198312013092240
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 351:2817-26. doi:10.1056/NEJMoa041588
15. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogen-and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 26:2473-81. doi:10.1200/JCO.2007.13.6424
16. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R. Semi-quantitative immunohistochemical assay versus oncotype DX(R) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol (2012) 25:869-76. doi:10.1038/modpathol.2011.219
17. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol (1997) 15:2894-904.
18. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol (1995) 17:15-21.
19. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer (1999) 85:1894-902. doi:10.1002/(SICI)1097-0142(19990501)85:93.0.CO;2-J
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344:783-92. doi:10.1056/NEJM200103153441101
21. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 354:809-20. doi:10.1056/NEJMoa053028
22. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer (2005) 6:240-6. doi:10.3816/CBC.2005.n.026
23. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin (2011) 61:365-81. doi:10.3322/caac.20135
24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-12. doi:10.1126/science.2470152
25. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 131:18-43. doi:10.1043/1543-2165(2007)131
26. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol (2011) 29:e458. doi:10.1200/JCO.2011.35.2245
27. Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med (2009) 133:775-80. doi:10.1043/1543-2165-133.5.775
28. Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, et al. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol (2010) 41:103-6. doi:10.1016/j.humpath.2009.07.001
29. Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol (2012) 25:1326-32. doi:10.1038/modpathol.2012.93
30. Jorgensen JT, Moller S, Rasmussen BB, Winther H, Schonau A, Knoop A. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. Am J Clin Pathol (2011) 136:145-51. doi:10.1309/AJCPJPJ8ZWGDTTWC
31. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol (2009) 27:1323-33. doi:10.1200/JCO.2007.14.8197
32. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol (2007) 25:1658-64. doi:10.1200/JCO.2006.08.1620
33. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 351:337-45. doi:10.1056/NEJMoa033025
34. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 23:1803-10. doi:10.1200/JCO.2005.08.037
35. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 24:4914-21. doi:10.1200/JCO.2006.06.7595
36. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 22:4772-8. doi:10.1200/JCO.2004.00.117
37. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit Rev Oncol Hematol (2013) 85:45-81. doi:10.1016/j.critrevonc.2012.05.001
38. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 6:1379-91. doi:10.1097/JTO.0b013e318220cb8e
39. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol (1998) 11:728-34.
40. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 279:577-80. doi:10.1126/science.279.5350.577
41. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med (2003) 349:1451-64. doi:10.1056/NEJMra020777
42. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donatodi Paola E, Dimitrijevic S, et al. Safety 740 and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a 741 phase I study. Lancet (2001) 358:1421-3. doi:10.1016/S0140-6736(01)06535-7
43. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 347:472-80. doi:10.1056/NEJMoa020461
44. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2004) 40:689-95. doi:10.1016/j.ejca.2003.11.025
45. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 21:4342-9. doi:10.1200/JCO.2003.04.190
46. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 28:889-94. doi:10.1097/00000478-200407000-00007
47. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561-6. doi:10.1038/nature05945
48. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 15:5216-23. doi:10.1158/1078-0432.CCR-09-0802
49. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 368:2385-94. doi:10.1056/NEJMoa1214886
50. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 461:245-57. doi:10.1007/s00428-012-1281-4
51. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer (2012) 77:288-92. doi:10.1016/j.lungcan.2012.03.004
52. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol (2011) 6:459-65. doi:10.1097/JTO.0b013e318209edb9
53. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol (2011) 6:466-72. doi:10.1097/JTO.0b013e31820b82e8
54. Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol (2013). doi:10.1038/modpathol.2013.87
55. Rothschild SI, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer (2013) 14:473-80. doi:10.1016/j.cllc.2013.04.006
56. Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer (2012) 118:4486-94. doi:10.1002/cncr.27411
57. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-54. doi:10.1038/nature00766
58. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 7:569-80. doi:10.1038/nrendo.2011.142
59. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 364:2305-15. doi:10.1056/NEJMoa1014209
60. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol (2008) 1:395-405. doi:10.1016/j.molonc.2007.12.003
61. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 363:809-19. doi:10.1056/NEJMoa1002011
62. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 380:358-65. doi:10.1016/S0140-6736(12)60868-X
63. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 122:11-9. doi:10.1007/s00401-011-0841-z
64. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol (2012) 123:223-33. doi:10.1007/s00401-011-0887-y
65. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 37:61-5. doi:10.1097/PAS.0b013e31826485c0
66. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn (2013) 15:94-100. doi:10.1016/j.jmoldx.2012.09.001
67. Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol (2013) 37:413-20. doi:10.1097/PAS.0b013e318271249e
68. Marin C, Beauchet A, Capper D, Zimmermann U, Julie C, Ilie M, et al. Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med (2013). doi:10.5858/arpa.2013-0031-OA
69. Yeh I, von Deimling A, Bastian BC. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst (2013) 105:917-9. doi:10.1093/jnci/djt119
70. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra-and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS ONE (2012) 7:e29336. doi:10.1371/journal.pone.0029336
71. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 104:464-8. doi:10.1038/sj.bjc.6606072
72. Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE, et al. (V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer (2013) 108:924-31. doi:10.1038/bjc.2013.29
73. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 361:958-67. doi:10.1056/NEJMoa0904554
74. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-500. doi:10.1126/science.1099314
75. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 126:651-5. doi:10.1002/ijc.24746
76. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350:2129-39. doi:10.1056/NEJMoa040938
77. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 23:5900-9. doi:10.1200/JCO.2005.02.857
78. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 7:169-81. doi:10.1038/nrc2088
79. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn (2010) 12:169-76. doi:10.2353/jmoldx.2010.090140
80. Fan X, Liu B, Xu H, Yu B, Shi S, Zhang J, et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol (2013) 44:1499-507. doi:10.1016/j.humpath.2012.12.002
81. Ho HL, Chang FP, Ma HH, Liao LR, Chuang YT, Chang-Chien YC, et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese cases with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology (2013). doi:10.1111/resp.12148
82. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol (2010) 5:1551-8. doi:10.1097/JTO.0b013e3181e9da60
83. Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, Tsai MF, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE (2011) 6:e23303. doi:10.1371/journal.pone.0023303
84. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res (2010) 16:3349-55. doi:10.1158/1078-0432.CCR-10-0129
85. Angulo B, Conde E, Suarez-Gauthier A, Plaza C, Martinez R, Redondo P, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS ONE (2012) 7:e43842. doi:10.1371/journal.pone.0043842
86. Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, et al. Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol (2013) 8:27. doi:10.1186/1746-1596-8-27
87. Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer (2012) 78:39-44. doi:10.1016/j.lungcan.2012.07.002
88. Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol (2012) 7:122-7. doi:10.1097/JTO.0b013e31822eeba2
89. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer (2011) 73:45-50. doi:10.1016/j.lungcan.2010.11.003
90. Wootla B, Denic A, Rodriguez M. Polyclonal and monoclonal antibodies in clinic. Methods Mol Biol (2014) 1060:79-110. doi:10.1007/978-1-62703-586-6_5
91. Saito M, Sakurai S, Motegi A, Saito K, Sano T, Nakajima T. Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. Pathol Int (2007) 57:200-4. doi:10.1111/j.1440-1827.2007.02081.x
92. Michel MC, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol (2009) 379:385-8. doi:10.1007/s00210-009-0395-y
93. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol (2002) 197:155-62. doi:10.1002/path.1077
94. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, et al. Antibody validation. Biotechniques (2010) 48:197-209. doi:10.2144/000113382
95. Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr Opin Biotechnol (2011) 22:882-7. doi:10.1016/j.copbio.2011.06.007
96. Lofblom J, Frejd FY, Stahl S. Non-immunoglobulin based protein scaffolds. Curr Opin Biotechnol (2011) 22:843-8. doi:10.1016/j.copbio.2011.06.002
97. Wurch T, Lowe P, Beck A, Corvaia N. Protein scaffolds as alternatives to whole antibodies: from discovery research to clinical development. Med Sci (Paris) (2009) 25:1169-72. doi:10.1051/medsci/200925121169
98. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23:1126-36. doi:10.1038/nbt1142
99. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature (1993) 363:446-8. doi:10.1038/363446a0
100. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett (1997) 414:521-6. doi:10.1016/S0014-5793(97)01062-4
101. Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeyen ME. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat Biotechnol (2003) 21:77-80. doi:10.1038/nbt772
102. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods (2006) 3:887-9. doi:10.1038/nmeth953
103. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol (2001) 74:277-302. doi:10.1016/S1389-0352(01)00021-6
104. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel (2007) 10:167-75.
105. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett (2010) 584:2670-80. doi:10.1016/j.febslet.2010.04.014
106. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel (2007) 20:189-99. doi:10.1093/protein/gzm011
107. Hoyer W, Gronwall C, Jonsson A, Stahl S, Hard T. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc Natl Acad Sci U S A (2008) 105:5099-104. doi:10.1073/pnas.0711731105
108. Gronwall C, Snelders E, Palm AJ, Eriksson F, Herne N, Stahl S. Generation of Affibody ligands binding interleukin-2 receptor alpha/CD25. Biotechnol Appl Biochem (2008) 50:97-112. doi:10.1042/BA20070261
109. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 35:1008-18. doi:10.1007/s00259-007-0658-0
110. Tran T, Orlova A, Sivaev I, Sandstrom M, Tolmachev V. Comparison of benzoate-and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. Int J Mol Med (2007) 19:485-93.
111. Stumpp MT, Amstutz P. DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 10:153-9.
112. Boersma YL, Pluckthun A. DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr Opin Biotechnol (2011) 22:849-57. doi:10.1016/j.copbio.2011.06.004
113. Theurillat JP, Dreier B, Nagy-Davidescu G, Seifert B, Behnke S, Zurrer-Hardi U, et al. Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. Mod Pathol (2010) 23:1289-97. doi:10.1038/modpathol.2010.103
114. Simon M, Zangemeister-Wittke U, Pluckthun A. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjug Chem (2012) 23:279-86. doi:10.1021/bc200591x
115. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem (2011) 18:4206-14. doi:10.2174/092986711797189600
116. Hu M, Zhang K. The application of aptamers in cancer research: an up-to-date review. Future Oncol (2013) 9:369-76. doi:10.2217/fon.12.201
117. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A (2006) 103:11838-43. doi:10.1073/pnas.0602615103
118. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation (2007) 116:2678-86. doi:10.1161/CIRCULATIONAHA.107.724864
119. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol (1995) 2:683-95. doi:10.1016/1074-5521(95)90032-2
120. Green LS, Jellinek D, Jenison R, Ostman A, Heldin CH, Janjic N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry (1996) 35:14413-24. doi:10.1021/bi961544+
121. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res (2002) 62:4029-33.
122. Casado P, Alcolea MP, Iorio F, Rodriguez-Prados JC, Vanhaesebroeck B, Saez-Rodriguez J, et al. Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol (2013) 14:R37. doi:10.1186/gb-2013-14-4-r37
123. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
124. Soderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods (2008) 45:227-32. doi:10.1016/j.ymeth.2008.06.014
125. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods (2006) 3:995-1000. doi:10.1038/nmeth947
126. Fredriksson S, Gullberg M, Jarvius J, Olsson C, Pietras K, Gustafsdottir SM, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol (2002) 20:473-7. doi:10.1038/nbt0502-473
127. Zieba A, Wahlby C, Hjelm F, Jordan L, Berg J, Landegren U, et al. Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection. Clin Chem (2010) 56:99-110. doi:10.1373/clinchem.2009.134452
128. Clausson CM, Allalou A, Weibrecht I, Mahmoudi S, Farnebo M, Landegren U, et al. Increasing the dynamic range of in situ PLA. Nat Methods (2011) 8:892-3. doi:10.1038/nmeth.1743
129. Leuchowius KJ, Clausson CM, Grannas K, Erbilgin Y, Botling J, Zieba A, et al. Parallel visualization of multiple protein complexes in individual cells in tumor tissue. Mol Cell Proteomics (2013) 12:1563-71. doi:10.1074/mcp.O112.023374
130. Gajadhar AS, Bogdanovic E, Munoz DM, Guha A. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res (2012) 10:428-40. doi:10.1158/1541-7786.MCR-11-0531
131. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat (2012) 132:463-70. doi:10.1007/s10549-011-1606-z
132. Leuchowius KJ, Jarvius M, Wickstrom M, Rickardson L, Landegren U, Larsson R, et al. High content screening for inhibitors of protein interactions and post-translational modifications in primary cells by proximity ligation. Mol Cell Proteomics (2010) 9:178-83. doi:10.1074/mcp.M900331-MCP200
133. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol (2010) 28:1248-50. doi:10.1038/nbt1210-1248
134. Ponten F, Schwenk JM, Asplund A, Edqvist PH. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med (2011) 270:428-46. doi:10.1111/j.1365-2796.2011.02427.x